|
1
|
Tomlinson B, Chan P and Lam CW:
Postprandial hyperlipidemia as a risk factor in patients with type
2 diabetes. Expert Rev Endocrinol Metab. 15:147–157.
2020.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Zhu JR, Gao RL and Zhao SP: Guidelines for
the prevention and treatment of dyslipidemia in Chinese adults
(Revised edition 2016). Chinese Circulation Journal. 31:937–953.
2016.(in Chinese).
|
|
3
|
Wang L, Lu MY, Ren JY and Chen H:
Correlation study on different dyslipidemia classification and
glucose metabolism in patients with hyperlipidemia. Beijing Da Xue
Xue Bao Yi Xue Ban. 43:427–431. 2011.PubMed/NCBI(In Chinese).
|
|
4
|
Koundouros N and Blenis J: Targeting mTOR
in the context of diet and whole-body metabolism. Endocrinology.
163(bqac041)2022.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Dennis MD, Coleman CS, Berg A, Jefferson
LS and Kimball SR: REDD1 enhances protein phosphatase 2A-mediated
dephosphorylation of Akt to repress mTORC1 signaling. Sci Signal.
7(ra68)2014.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Ellisen LW, Ramsayer KD, Johannessen CM,
Yang A, Beppu H, Minda K, Oliner JD, McKeon F and Haber DA: REDD1,
a developmentally regulated transcriptional target of p63 and p53,
links p63 to regulation of reactive oxygen species. Mol Cell.
10:995–1005. 2002.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Kimball SR, Do AN, Kutzler L, Cavener DR
and Jefferson LS: Jefferson LS rapid turnover of the mTOR complex 1
(mTORC1) repressor REDD1 and activation of mTORC1 signaling
following inhibition of protein synthesis. Biol Chem.
283:3465–3475. 2008.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Katiyar S, Liu E, Knutzen CA, Lang ES,
Lombardo CR, Sankar S, Toth JI, Petroski MD, Ronai Z and Chiang GG:
REDD1, an inhibitor of mTOR signalling, is regulated by the
CUL4A-DDB1 ubiquitin ligase. EMBO Rep. 10:866–872. 2009.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Papapanagiotou A, Siasos G, Kassi E,
Gargalionis AN and Papavassiliou AG: Novel inflammatory markers in
hyperlipidemia: Clinical implications. Curr Med Chem. 22:2727–2743.
2015.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Siasos G, Tousoulis D, Oikonomou E,
Zaromitidou M, Stefanadis C and Papavassiliou AG: Inflammatory
markers in hyperlipidemia: From experimental models to clinical
practice. Curr Pharm Des. 17:4132–4146. 2011.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Butani L, Dharmar M, Devaraj S and Jialal
I: Preliminary report of inflammatory markers, oxidative stress,
and insulin resistance in adolescents of different ethnicities.
Metab Syndr Relat Disord. 14:182–186. 2016.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Tarantino G, Citro V, Balsano C and Capone
D: Could SCGF-beta levels be associated with inflammation markers
and insulin resistance in male patients suffering from
obesity-related NAFLD? Diagnostics (Basel). 10(395)2020.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Chinese Adult Dyslipidemia Prevention and
Treatment Guidelines Revision Joint Committee: Guidelines for the
prevention and treatment of dyslipidemia in Chinese adults (Revised
edition 2016). Chinese Journal of General Practitioners 16: 15-35,
2017 (in Chinese).
|
|
14
|
Sun J, Du Q and Wang GP: Research on β
cell function and insulin resistance in patients with type 2
diabetes mellitus. Chin J Diabetes. 23:592–594. 2015.
|
|
15
|
Xiao-Yan X, Wen-Ying Y and Zhao-Jun Y: The
diagnostic significance of homeostasis model assessment of insulin
resistance in metabolic syndrome among subjects with different
glucose tolerance. Chinese J Diabetes Mellitus. 2004:31–35.
2004.
|
|
16
|
Yuan H and Yuan F: Study on the
relationship between pure hyperlipidemia and insulin resistance
index. Chinese Journal of Practical Internal Medicine. 27:246–247.
2007.(in Chinese).
|
|
17
|
Qiu LQ: Comparison of clinical effects of
two statins in the treatment of primary hyperlipidemia. Guide of
China Medicine. 9:85–86. 2011.(in Chinese).
|
|
18
|
Wang XG and Zhao X: Research progress of
pathogenesis and treatment of hyperlipidemia. Journal of Liaoning
University of Traditional Chinese Medicine. 22:196–200. 2020.(in
Chinese).
|
|
19
|
Schmelzle T and Hall MN: TOR, a central
controller of cell growth. Cell. 103:253–262. 2000.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Sudarsanam S and Johnson DE: Functional
consequences of mTOR inhibition. Curr Opin Drug Discov Devel.
13:31–40. 2010.PubMed/NCBI
|
|
21
|
Laplante M and Sabatini DM: mTOR signaling
in growth control and disease. Cell. 149:274–293. 2012.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Carlson CJ, White MF and Rondinone CM:
Mammalian target of rapamycin regulates IRS-1 serine 307
phosphorylation. Biochem Biophys Res Commun. 316:533–539.
2004.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Sarbassov DD, Ali SM and Sabatini DM:
Growing roles for the mTOR pathway. Curr Opin Cell Biol.
17:596–603. 2005.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Ozes ON, Akca H, Mayo LD, Gustin JA,
Maehama T, Dixon JE and Donner DB: A phosphatidylinositol
3-kinase/Akt/mTOR pathway mediates and PTEN antagonizes tumor
necrosis factor inhibition of insulin signaling through insulin
receptor substrate-1. Proc Natl Acad Sci USA. 98:4640–4645.
2001.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Ting H, Zhen-Zhen L, Yang B and Hui-Shuang
L: Probiotics improve lipid metabolism of obese mice induced by
high-fat and high-sucrose diet. Basic Clin Med. 41:1260–1265.
2021.
|
|
26
|
Ding L and Liu YC: Study on improving
nonalcoholic fatty liver disease of high fat diet induced rats by
corn silk aqueous extract. China Food Additives. 32:51–57. 2021.(in
Chinese).
|
|
27
|
Gordon BS, Williamson DL, Lang CH,
Jefferson LS and Kimball SR: Nutrient-induced stimulation of
protein synthesis in mouse skeletal muscle is limited by the mTORC1
repressor REDD1. J Nutr. 145:708–713. 2015.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Dungan CM and Williamson DL: Regulation of
skeletal muscle insulin-stimulated signaling through the
MEK-REDD1-mTOR axis. Biochem Biophys Res Commun. 482:1067–1072.
2017.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Dungan CM, Wright DC and Williamson DL:
Lack of REDD1 reduces whole body glucose and insulin tolerance, and
impairs skeletal muscle insulin signaling. Biochem Biophys Res
Commun. 453:778–783. 2014.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Regazzetti C, Dumas K, Marchand-Brustel
YL, Peraldi P, Tanti JF and Giorgetti-Peraldi S: Regulated in
development and DNA damage responses -1 (REDD1) protein contributes
to insulin signaling pathway in adipocytes. PLoS One.
7(e52154)2012.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Sarbassov DD, Ali SM, Sengupta S, Sheen
JH, Hsu PP, Bagley AF, Markhard AL and Sabatini DM: Prolonged
rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell.
22:159–168. 2006.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Wang H, Wang JM, Qu H, Wei H, Ji B, Yang
Z, Wu J, He Q, Luo Y, Liu D, et al: In vitro and in vivo inhibition
of mTOR by 1,25-dihydroxyvitamin D3 to improve early diabetic
nephropathy via the DDIT4/TSC2/mTOR pathway. Endocrine. 54:348–359.
2016.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Yang Z, Liu F, Qu H, Wang H, Xiao X and
Deng H: 1,25(OH)2D3 protects cell against high
glucose-induced apoptosis through mTOR suppressing. Mol Cell
Endocrinol. 414:111–119. 2015.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Liang D, Zhao SQ, Li ZY, Xiao YW, Ding J,
Xiao Y and Guo B: miR-22 promotes DNA damage of renal tubular
epithelial cells with diabetic kidney disease by inhibiting DDIT4.
Chin J Pathophysiol. 37:1933–1941. 2021.(In Chinese).
|
|
35
|
Xu MC, Shi HM, Wang H and Gao XF:
Salidroside protects against hydrogen peroxide-induced injury in
HUVECs via the regulation of REDD1 and mTOR activation. Mol Med
Rep. 8:147–153. 2013.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Jin HO, Seo SK, Woo SH, Kim ES, Lee HC,
Yoo DH, An S, Choe TB, Lee SJ, Hong SI, et al: Activating
transcription factor 4 and CCAAT/enhancer-binding protein-beta
negatively regulate the mammalian target of rapamycin via Redd1
expression in response to oxidative and endoplasmic reticulum
stress. Free Radic Biol Med. 46:1158–1167. 2009.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Whitney ML, Jefferson LS and Kimball SR:
ATF4 is necessary and sufficient for ER stress-induced upregulation
of REDD1 expression. Biochem Biophys Res Commun. 379:451–455.
2009.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Chen DP, Ma YP, Zhuo L, Zhang Z, Zou GM,
Yang Y, Gao HM and Li WG: 1,25-Dihydroxyvitamin D3 inhibits the
proliferation of rat mesangial cells induced by high glucose via
DDIT4. Oncotarget. 9:418–427. 2018.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Chen H, Chen Y, Wu W, Chen Z, Cai Z, Ch Z,
Yan X and Wu S: Prolonged hyperlipidemia exposure increases the
risk of arterial stiffness in young adults: A cross-sectional study
in a cohort of Chinese. BMC Public Health. 20:1091–1099.
2020.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Miao J, Zang X, Cui X and Zhang J:
Autophagy, hyperlipidemia, and atherosclerosis. Adv Exp Med Biol.
1207:237–264. 2020.PubMed/NCBI View Article : Google Scholar
|
|
41
|
López-Mejías R, Genre F, Remuzgo-Martínez
S, González-Juanatey C, Robustillo-Villarino M, Llorca J, Corrales
A, Vicente E, Miranda-Filloy JA, Magro C, et al: Influence of
elevated-CRP level-related polymorphisms in non-rheumatic
Caucasians on the risk of subclinical atherosclerosis and
cardiovascular disease in rheumatoid arthritis. Sci Rep.
6(31979)2016.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Chang CJ, Jian DY, Lin MW, Zhao JZ, Ho LT
and Juan CC: Evidence in obese children: contribution of
hyperlipidemia, obesity-inflammation, and insulin sensitivity. PLoS
One. 10(e0125935)2015.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Lin MW, Hwu CM, Huang YH, Sheu WH, Shih
KC, Chiang FT, Olshen R, Chen YD, Curb JD, Rodriguez B, et al:
Directly measured insulin resistance and the assessment of
clustered cardiovascular risks in hypertension. Am J Hypertens.
19:1118–1124. 2006.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Ding D, Li X, Qiu J, Li R, Zhang Y, Su D,
Li Z, Wang M, Lv X and Wang D: , et al: Serum lipids,
apolipoproteins, and mortality among coronary artery disease
patients. Biomed Res Int. 2014(709756)2014.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Wang X, Bao W, Liu J, Ouyang YY, Wang D,
Rong S, Xiao X, Shan ZL, Zhang Y, Yao P and Liu LG: Inflammatory
markers and risk of type 2 diabetes: A systematic review and
meta-analysis. Diabetes Care. 36:166–175. 2013.PubMed/NCBI View Article : Google Scholar
|
